Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases
Abstract Coronavirus disease 2019 (COVID-19), which spread worldwide from Wuhan, China, in 2019, appeared for a time to be overcome by the remarkable efficacy of mRNA vaccines; however, new variants of severe acute respiratory syndrome coronavirus 2 have emerged and remain rampant. The involvement o...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-01-01
|
| Series: | Inflammation and Regeneration |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41232-022-00247-1 |
| _version_ | 1797958838649880576 |
|---|---|
| author | Yasuhiro Kato Takayoshi Morita Atsushi Kumanogoh |
| author_facet | Yasuhiro Kato Takayoshi Morita Atsushi Kumanogoh |
| author_sort | Yasuhiro Kato |
| collection | DOAJ |
| description | Abstract Coronavirus disease 2019 (COVID-19), which spread worldwide from Wuhan, China, in 2019, appeared for a time to be overcome by the remarkable efficacy of mRNA vaccines; however, new variants of severe acute respiratory syndrome coronavirus 2 have emerged and remain rampant. The involvement of the virus in the emergence of variant strains and the relationship between vaccine efficacy and immunosuppressive drugs have attracted significant attention, particularly with regard to patients with autoimmune inflammatory rheumatic disease (AIRD) who take immunosuppressive drugs. This review outlines the relationship between mRNA vaccines, one of the key strategies against COVID-19, and AIRD and discusses the immune response elicited by mRNA vaccines. Furthermore, the impact of immunosuppressive agents on the mRNA vaccine-induced immune response in patients with AIRD and side effects of the vaccine, such as exacerbation of the underlying disease, is outlined. |
| first_indexed | 2024-04-11T00:24:29Z |
| format | Article |
| id | doaj.art-d6c6f71ba72a4021a7576bb8e40e366b |
| institution | Directory Open Access Journal |
| issn | 1880-8190 |
| language | English |
| last_indexed | 2024-04-11T00:24:29Z |
| publishDate | 2023-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Inflammation and Regeneration |
| spelling | doaj.art-d6c6f71ba72a4021a7576bb8e40e366b2023-01-08T12:07:04ZengBMCInflammation and Regeneration1880-81902023-01-014311610.1186/s41232-022-00247-1Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseasesYasuhiro Kato0Takayoshi Morita1Atsushi Kumanogoh2Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of MedicineDepartment of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of MedicineDepartment of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of MedicineAbstract Coronavirus disease 2019 (COVID-19), which spread worldwide from Wuhan, China, in 2019, appeared for a time to be overcome by the remarkable efficacy of mRNA vaccines; however, new variants of severe acute respiratory syndrome coronavirus 2 have emerged and remain rampant. The involvement of the virus in the emergence of variant strains and the relationship between vaccine efficacy and immunosuppressive drugs have attracted significant attention, particularly with regard to patients with autoimmune inflammatory rheumatic disease (AIRD) who take immunosuppressive drugs. This review outlines the relationship between mRNA vaccines, one of the key strategies against COVID-19, and AIRD and discusses the immune response elicited by mRNA vaccines. Furthermore, the impact of immunosuppressive agents on the mRNA vaccine-induced immune response in patients with AIRD and side effects of the vaccine, such as exacerbation of the underlying disease, is outlined.https://doi.org/10.1186/s41232-022-00247-1COVID-19SARS-CoV-2Autoimmune inflammatory rheumatic disease (AIRD)mRNA vaccineImmune response |
| spellingShingle | Yasuhiro Kato Takayoshi Morita Atsushi Kumanogoh Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases Inflammation and Regeneration COVID-19 SARS-CoV-2 Autoimmune inflammatory rheumatic disease (AIRD) mRNA vaccine Immune response |
| title | Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases |
| title_full | Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases |
| title_fullStr | Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases |
| title_full_unstemmed | Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases |
| title_short | Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases |
| title_sort | efficacy and risk of mrna vaccination in patients with autoimmune inflammatory rheumatic diseases |
| topic | COVID-19 SARS-CoV-2 Autoimmune inflammatory rheumatic disease (AIRD) mRNA vaccine Immune response |
| url | https://doi.org/10.1186/s41232-022-00247-1 |
| work_keys_str_mv | AT yasuhirokato efficacyandriskofmrnavaccinationinpatientswithautoimmuneinflammatoryrheumaticdiseases AT takayoshimorita efficacyandriskofmrnavaccinationinpatientswithautoimmuneinflammatoryrheumaticdiseases AT atsushikumanogoh efficacyandriskofmrnavaccinationinpatientswithautoimmuneinflammatoryrheumaticdiseases |